Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2023 | The importance of MRD monitoring in patients with AML

Farhad Ravandi • 21 Mar 2023
ISAL 2023
Acute Myeloid Leukemia Leukemia

Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights the importance of measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML), and further comments on the value of improving assays used for MRD detection. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

Disclosures

Consultant for: Celgene/BMS, Astellas, Abbvie, Novartis, Syros, Taiho/Astex, Kite Pharma, Grant/Research support from: Amgen, Xencor, Astex/Taiho, Abbvie, Syros, Prelude, Honoraria from: Celgene/BMS, Astellas, Abbvie, Novartis, Syros, Taiho/Astex, Kite Pharma

More from Farhad Ravandi

Can persistent MRD negativity be considered therapy failure in AML? ELN definitions and relapse risk
2:04
Can persistent MRD negativity be considered therapy failure in AML? ELN definitions and relapse risk
Farhad Ravandi • 21 Sep 2026
Refining the role of MRD in AML: predicting relapse and the goal of MRD negativity
1:40
Refining the role of MRD in AML: predicting relapse and the goal of MRD negativity
Farhad Ravandi • 21 Sep 2026
Will MRD eradication become a routine treatment goal in AML?
1:09
Will MRD eradication become a routine treatment goal in AML?
Farhad Ravandi • 21 Sep 2026
Can current MRD assays accurately predict relapse in AML? Limitations and future directions
2:18
Can current MRD assays accurately predict relapse in AML? Limitations and future directions
Farhad Ravandi • 21 Sep 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals